KRAS G12D
10
5
7
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (10)
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors
RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors